Clinical Trials Directory

Trials / Conditions / Arthroplasty, Replacement

Arthroplasty, Replacement

14 registered clinical trials studyying Arthroplasty, Replacement — 1 currently recruiting.

StatusTrialSponsorPhase
UnknownSMR Stemless Reverse Vs SMR Reverse Shoulder System
NCT04697004
Limacorporate S.p.aN/A
UnknownEffectiveness of a Novel Gaming System on Post-operative Rehabilitation Outcomes After Total Knee Arthroplasty
NCT04080401
Tan Tock Seng HospitalN/A
CompletedAn Evaluation of Clotting Factor Activity Before and After Total Hip Arthroplasty
NCT04372173
Military Institute od Medicine National Research Institute—
CompletedPatient-Centered Weight Loss Program for Knee Replacement Patients
NCT02728661
Northwestern UniversityPhase 1 / Phase 2
CompletedWound Additives in Primary Total Joint Athroplasty
NCT03158623
Salt Lake Orthopedic ClinicPhase 3
CompletedThe Impact of Medicare Bundled Payments
NCT03407885
Amy FinkelsteinN/A
CompletedEffect of Dexmedetomidine on Ischemia-Reperfusion Injury in Lower Extremity Operations
NCT02648958
Yonsei UniversityN/A
CompletedEfficacy of Surgical Preparation Solutions in Knee Surgery
NCT01857349
Texas Tech University Health Sciences CenterN/A
RecruitingAmerican Joint Replacement Registry
NCT01909375
American Joint Replacement Registry—
CompletedTreatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Ete
NCT01184989
Boehringer IngelheimPhase 4
TerminatedPradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
NCT01153698
Boehringer Ingelheim—
CompletedPradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replac
NCT00847301
Boehringer Ingelheim—
CompletedPradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery
NCT00846807
Boehringer Ingelheim—
UnknownTrial to Reduce Antimicrobial Prophylaxis Errors (TRAPE)
NCT00114036
Agency for Healthcare Research and Quality (AHRQ)N/A